New-generation incubator brings the latest technology to mid-capacity microplate cell culture
New Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator delivers robust and reliable culture solution for cell-based pharmaceutical applications.
As the pharmaceutical industry continues to increase its focus on the development of biologics, scientists require robust, automation-ready incubation solutions with the reliability and flexibility to support a range of discovery, development and processing applications for future cell-based and cell-derived medicines.
Underpinned by over 50 years of experience in advanced environmental chamber and incubation technology, the Thermo Scientific Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists in the pharmaceutical industry with an automation-ready, mid-capacity cell culture solution. The new automated incubator system delivers cell growth and environmental control across a range of microplate applications, including cell-based screening, immuno-capture assays, microbiology and enzyme testing. Designed for fast and flexible integration, the Cytomat 2 C-LiN Series Automated Incubator enhances laboratory automation installations.
Thermo Fisher Scientific is showcasing its new generation of automated incubators during the 2019 European conference and exhibition of the Society for Laboratory Automation and Screening (SLAS Europe) being held June 26–28, Booth #418 at the Centre de Convencions Internacional, Barcelona, Spain.
"With the increasing number of biotherapeutics in development and their ever-growing complexity, scientists need cell culture solutions they can trust to deliver dependable cellular growth within a controlled and contamination-free environment," said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific. "The launch of the Cytomat 2 C-LiN Series Automated Incubator brings the latest automation-ready incubation technology to mid-capacity microplate applications, enabling scientists to more easily sustain valuable and vital cell lines for the synthesis and development of future therapeutics."
The Cytomat 2 C-LiN Series Automated Incubator provides research scientists and cell culture biologists with
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance